Judge Rejects Prior Restraint For Tylenol Ads Ahead Of 'Bellwether' Trial
This article was originally published in The Tan Sheet
Executive Summary
J&J/McNeil may continue to advertise the Tylenol line ahead of the first case in multi-district litigation claiming use of the products as labeled is linked to liver damage, says a federal judge. The plaintiff asked the court to prohibit the firm from advertising that could taint the juror pool ahead of the fall trial.
You may also be interested in...
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor
Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.
J&J Argument Against Liver Damage Experts 'Borders On Ridiculous' – Judge
J&J fails in request to exclude two experts for the plaintiff in bellwether litigation alleging liver damage from indicated doses of Tylenol Extra Strength. The decision represents the second blow in less than a month in J&J's efforts to exclude plaintiff's evidence from the trial.